# Study Guide: 2026 ACC/AHA Clinical Practice Guideline Methodology This study guide provides a comprehensive overview of the methodology, governance, and rigorous processes employed by the American College of Cardiology (ACC) and the American Heart Association (AHA) to develop clinical practice guidelines. It is designed to assist stakeholders in understanding the framework used to synthesize scientific evidence into actionable clinical recommendations. --- ## Key Concepts and Organizational Framework ### Mission and Purpose The primary mission of ACC/AHA clinical practice guidelines is to improve cardiovascular health by providing clinicians with evidence-based recommendations. These guidelines define practices that meet the needs of most patients in most circumstances, assisting in clinical decision-making for the evaluation, diagnosis, prevention, and management of cardiovascular diseases. ### Core Principles of Recommendation Formulation All guidelines are developed based on three foundational values: 1. **Transparency:** Ensuring the process and evidence are clearly documented. 2. **Evidence-based:** Prioritizing high-quality scientific data over anecdotal experience. 3. **Patient-Centered:** Focusing on patient wellness, shared decision-making, and individual outcomes. ### Governance Structure The **Joint Committee on Clinical Practice Guidelines (Joint Committee)** oversees the development process. * **Composition:** 16 members (Chair, Chair-Elect, and 14 voting members). * **Organization Balance:** Voting members are split equally between the ACC (7) and AHA (7). * **Representation:** Includes at least one Fellow-in-Training (FIT) or Early Career (EC) member. * **Terms:** The Chair serves one non-renewable 2-year term. Voting members serve 2-year terms, with a maximum of 4 consecutive years. --- ## The Guideline Development Process The methodology is structured into four primary phases, with a fifth phase dedicated to ongoing maintenance. ### Phase 0: Pre-Production This phase focuses on defining the scope and assembling the team. * **Writing Committee (WC) Formation:** Selection of experts, lay stakeholders, and patient representatives. * **Conflict of Interest:** Mandatory disclosure of all financial and intellectual relationships with industry (RWI). * **Scope Definition:** Identification of the primary audience (cardiovascular clinicians) and secondary audiences (payers, patients, and healthcare systems). ### Phase 1: Document Development * **PICO(TS) Format:** Clinical questions are framed using Population, Intervention, Comparator, Outcome, Timing, and Setting. * **Literature Search:** Conducted with the assistance of a medical librarian. * **Evidence Synthesis:** Writing Committee members review data and draft recommendations supported by evidence tables. ### Phase 2: Review and Approval * **Consensus Threshold:** A formal vote is required for recommendations; the threshold for consensus was recently updated to **>75%**. * **Peer Review:** A Peer Review Committee (PRC) of 20–30 individuals provides confidential feedback. The names of reviewers are withheld from the WC during the process to minimize bias. ### Phase 3: Organization Approval and Publication * Final manuscripts undergo governing body approval from both the ACC and AHA before being published in their respective journals. ### Phase 4: Post-Publication Surveillance * **Surveillance Committee:** Conducts ongoing reviews of new clinical trial evidence to determine if updates or revisions to existing guidelines are necessary. --- ## Classification Standards Recommendations are categorized by the **Class of Recommendation (COR)**, indicating the strength of the recommendation, and the **Level of Evidence (LOE)**, indicating the quality of the supporting data. ### Table 1: Class of Recommendation (COR) | Class | Strength | Benefit vs. Risk | | :--- | :--- | :--- | | **Class 1** | Strong | Benefit >>> Risk | | **Class 2a** | Moderate | Benefit >> Risk | | **Class 2b** | Weak | Benefit ≥ Risk | | **Class 3: No Benefit** | Moderate | Benefit = Risk | | **Class 3: Harm** | Strong | Risk > Benefit | ### Table 2: Level of Evidence (LOE) | Level | Type of Evidence | | :--- | :--- | | **Level A** | High-quality evidence from >1 RCT or meta-analyses of high-quality RCTs. | | **Level B-R** | Moderate-quality evidence from 1 or more randomized trials (RCTs). | | **Level B-NR** | Moderate-quality evidence from nonrandomized, observational, or registry studies. | | **Level C-LD** | Randomized or nonrandomized studies with limitations in design or execution. | | **Level C-EO** | Consensus of expert opinion based on clinical experience. | --- ## Specialized Methodological Considerations ### Living Guidelines Model To improve timeliness and accessibility, the ACC/AHA is transitioning to a "Living Guidelines" model. This involves: * Timely updates in response to practice-changing evidence. * The use of a cloud-based "structured content" platform rather than static PDF documents. * Continuous process evaluation to reduce the time from research publication to guideline update. ### Shared Decision-Making (SDM) SDM is a collaborative process where clinicians and patients reach healthcare choices together. Guidelines incorporate SDM to ensure patient preferences and values are integrated into the care plan, often receiving a Class 1 recommendation. ### Patient-Reported Outcomes (PRO) Guidelines increasingly incorporate PROs (e.g., symptom relief, quality of life) to: * Guide treatments based on expected patient benefits. * Assess treatment adherence. * Integrate the "value" of care (Quality-Adjusted Life Years). --- ## Short-Answer Practice Questions 1. **What is the required consensus threshold for a Writing Committee to approve a recommendation?** * *Answer:* Greater than 75%. 2. **How many members constitute the Joint Committee on Clinical Practice Guidelines?** * *Answer:* 16 members (14 voting members, 1 Chair, and 1 Chair-Elect). 3. **What does the acronym PICO(TS) stand for?** * *Answer:* Population, Intervention, Comparator, Outcome, Timing, and Setting. 4. **Distinguish between LOE B-R and LOE B-NR.** * *Answer:* LOE B-R is derived from randomized trials, while LOE B-NR is derived from nonrandomized, observational, or registry studies. 5. **What are the three core principles used in the development of ACC/AHA recommendations?** * *Answer:* Transparency, Evidence-based, and Patient-Centered. 6. **Who is the primary intended audience for ACC/AHA clinical practice guidelines?** * *Answer:* The general cardiovascular clinician. 7. **What is the purpose of the "Modular Format" in guideline publication?** * *Answer:* To allow for easier digital integration and frequent updates of specific recommendations as new literature becomes available. 8. **When is a formal Systematic Review (SR) performed?** * *Answer:* When warranted by available evidence using a focused approach to a well-defined topic, based on specific criteria evaluated by the Joint Committee. 9. **What is the maximum term a voting member of the Joint Committee can serve?** * *Answer:* A maximum of 4 consecutive years (two 2-year terms). 10. **What role do "Lay Stakeholders" play in the Writing Committee?** * *Answer:* They provide the patient or representative perspective to ensure the guidelines remain patient-centered. --- ## Essay Prompts for Deeper Exploration 1. **The Evolution of Evidence Synthesis:** Discuss the significance of moving from "expert-led" guidelines to the modern ACC/AHA framework of Class of Recommendation (COR) and Level of Evidence (LOE). How does this transition enhance the trustworthiness of clinical advice? 2. **The Living Guidelines Model:** Evaluate the necessity of the Living Guidelines Model in the current technological and scientific landscape. What are the potential challenges and benefits of moving away from traditional PDF-based publications to a structured, cloud-based content system? 3. **Incorporating Economic Value:** Analyze the role of cost and value analyses (using ICER and QALY) in guideline development. Should economic factors influence the Class of Recommendation, or should they remain secondary to clinical efficacy? Use the provided methodology for "Economic Value Statements" to support your argument. 4. **Shared Decision-Making and Patient Autonomy:** Explore how the inclusion of Shared Decision-Making (SDM) and Patient-Reported Outcomes (PRO) changes the dynamic of the clinician-patient relationship. How do these elements ensure that guidelines are "actionable" but not "prescriptive"? --- ## Glossary of Important Terms * **Class of Recommendation (COR):** A designation indicating the strength of a recommendation based on the magnitude of benefit versus risk. * **Evidence Review Committee (ERC):** A group commissioned to perform formal systematic reviews when specific criteria are met. * **Incremental Cost-Effectiveness Ratio (ICER):** A statistic used in economic analysis to compare the cost and health outcomes of different treatment strategies. * **Level of Evidence (LOE):** A designation indicating the quality and type of scientific data supporting a recommendation. * **Mendelian Randomization (MR):** A method of using measured variation in genes to examine the causal effect of a modifiable exposure on disease. * **PICO(TS):** A structured framework used to develop clinical questions (Population, Intervention, Comparator, Outcome, Timing, Setting). * **Quality-Adjusted Life Year (QALY):** A generic measure of disease burden, including both the quality and the quantity of life lived; used in economic evaluations. * **Relationships with Industry (RWI):** Potential conflicts of interest involving financial or intellectual ties to commercial entities that must be disclosed by all committee members. * **Writing Committee (WC):** A multidisciplinary group of experts and lay representatives responsible for drafting the guideline recommendations and supportive text.